Wockhardt Ltd. is a flagship company of the Wockhardt Group and is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalization and biotechnology. The Company has a market capitalization of US$ 1.3 billion and an annual turnover of US$ 285 million (Rs. 1,239 million).

Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with half of its revenue coming from Europe and the United States.

Read more about Wockhardt Limited at www.wockhardt.com

Wockhardt acquired UK based CP Pharmaceuticals Limited to fuels its European growth and became one of the top 10 generic pharmaceutical companies in the UK.

CP Pharmaceuticals has four key businesses consisting of a branded portfolio of hospital drugs, generics, contract manufacturing and exports. It has 225 product licenses, providing the company with a significant growth potential and has spent over seven million sterling pounds on acquiring brands in recent years.

Read more about CP pharmaceuticals at www.cppharma.co.uk

Wockhardt acquired Espharma GmbH in 2004 to further strengthen its presence in the German and European market.

Espharma has a sizeable portfolio of 135 marketing authorizations, of which 67 are in Germany. The company also has nine international patents and 94 trademarks.

Read more about Espharma GmbH at
www.esparma.de